Superior efficacy and tolerance of reduced doses of vemurafenib plus anakinra in Erdheim-Chester disease: Towards the paradigm of combined targeting and immune therapies

Authors

  • Fréderic Franconieri Department of Internal Medicine and Clinical Immunology, CHU Côte De Nacre, Université Basse Normandie, Caen, France
  • Nicolas Martin-Silva Department of Internal Medicine and Clinical Immunology, CHU Côte De Nacre, Université Basse Normandie, Caen, France
  • Hubert de Boysson Department of Internal Medicine and Clinical Immunology, CHU Côte De Nacre, Université Basse Normandie, Caen, France
  • Françoise Galateau-Salle Department of Pathology, CHU Côte De Nacre, Université Basse Normandie, Caen, France
  • Jean-François Emile Department of Pathology, CHU Ambroise Paré, Boulogne, France
  • Boris Bienvenu Department of Internal Medicine and Clinical Immunology, CHU Côte De Nacre, Université Basse Normandie, Caen, France
  • Achille Aouba Department of Internal Medicine and Clinical Immunology, CHU Côte De Nacre, Université Basse Normandie, Caen, France

DOI:

https://doi.org/10.3109/0284186X.2015.1120885

Abstract

No abstract available

Downloads

Download data is not yet available.

Downloads

Published

2016-07-02

How to Cite

Franconieri, F., Martin-Silva, N., de Boysson, H., Galateau-Salle, F., Emile, J.-F., Bienvenu, B., & Aouba, A. (2016). Superior efficacy and tolerance of reduced doses of vemurafenib plus anakinra in Erdheim-Chester disease: Towards the paradigm of combined targeting and immune therapies. Acta Oncologica, 55(7), 930–932. https://doi.org/10.3109/0284186X.2015.1120885

Issue

Vol. 55 No. 7 (2016): Acta Oncologica

Section

Articles